Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
BioPharma Dive8h
J&J antidepressant eases symptoms, improves sleep in key trial
The company has put high expectations on the drug, an orexin-2 antagonist called seltorexant, as a cornerstone of its neuropsychiatry pipeline.
Marcus King on Battling Feelings of “Terrible Hopelessness” with Meaningful Communication: Podcast
The singer-songwriter talks about the importance of having the language to express one's experiences to others. Marcus King on Battling Feelings of “Terrible Hopelessness” with Meaningful Communicatio ...
Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - - ...
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As we delve deeper into 2024, biotech stocks are commanding the attention of ...
bovnews6d
It’s an all-out bull run for Alkermes plc (ALKS) Stock
Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...